Ro 08-2750

Ro 08-2750 is a non-peptide and reversible nerve growth factor (NGF) inhibitor which binds to NGF, and with an IC50 of ~ 1 μM. Ro 08-2750 inhibits NGF binding to p75NTR selectively over TRKA[1]. Ro 08-2750 is a selective MSI RNA-binding activity inhibitor, with an IC50 of 2.7 μM[3].

Product Specifications

CAS Number

[37854-59-4]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis

Type

Reference compound

Related Pathways

Apoptosis

Applications

Cancer-programmed cell death

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/ro-08-2750.html

Purity

98.01

Solubility

DMSO : 4 mg/mL (ultrasonic; warming; heat to 80°C)

Smiles

O=CC1=C(C)C=C2N=C3C(NC(N=C3N(C)C2=C1)=O)=O

Molecular Formula

C13H10N4O3

Molecular Weight

270.24

Precautions

H302, H315, H319, H335

References & Citations

[1]Arkin MR, et al. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Discov. 2004 Apr;3 (4) :301-17.|[2]Niederhauser O, et al. NGF ligand alters NGF signaling via p75 (NTR) and trkA. J Neurosci Res. 2000 Aug 1;61 (3) :263-72.|[3]Minuesa G, et al. Small-molecule targeting of MUSASHI RNA-binding activity in acute myeloid leukemia. Nat Commun. 2019 Jun 19;10 (1) :2691.